Last updated at 02 Jul 2024 04:38 AM
Director
DIN: 03605781
Abdul Samad Ojintakam is currently associated with 2 companies in various capacities such as Director and Partner. They serve as a Director at CALICUT MEDICARE AND PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 03605781.Abdul Samad Ojintakam has previously been associated with 1 company in roles such as Partner.Abdul Samad Ojintakam is currently involved in 2 different roles. Their most recent position is with CALICUT HEALTHCARE LLP as a Partner. The first company Abdul Samad Ojintakam was appointed to as a director was CALICUT MEDICARE AND PHARMA PRIVATE LIMITED. Abdul Samad Ojintakam is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Abdul Samad Ojintakam is currently associated with 2 companies in various capacities such as Director and Partner. They serve as a Director at CALICUT MEDICARE AND PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 03605781.Abdul Samad Ojintakam has previously been associated with 1 company in roles such as Partner.Abdul Samad Ojintakam is currently involved in 2 different roles. Their most recent position is with CALICUT HEALTHCARE LLP as a Partner. The first company Abdul Samad Ojintakam was appointed to as a director was CALICUT MEDICARE AND PHARMA PRIVATE LIMITED. Abdul Samad Ojintakam is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Gain instant access to verified contact details.
Current Companies (1)
Current LLPs (1)
Past Companies (1)
1y 8m 10 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| CALICUT MEDICARE AND PHARMA PRIVATE LIMITED | Director | 14-Sep-2017 |